PT2802652T - Enzimas de clostridium histolyticum - Google Patents
Enzimas de clostridium histolyticumInfo
- Publication number
- PT2802652T PT2802652T PT13736040T PT13736040T PT2802652T PT 2802652 T PT2802652 T PT 2802652T PT 13736040 T PT13736040 T PT 13736040T PT 13736040 T PT13736040 T PT 13736040T PT 2802652 T PT2802652 T PT 2802652T
- Authority
- PT
- Portugal
- Prior art keywords
- clostridium histolyticum
- enzyme
- histolyticum enzyme
- clostridium
- histolyticum
- Prior art date
Links
- 102000004190 Enzymes Human genes 0.000 title 1
- 108090000790 Enzymes Proteins 0.000 title 1
- 241000193159 Hathewaya histolytica Species 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24003—Microbial collagenase (3.4.24.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24027—Thermolysin (3.4.24.27)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96402—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals
- G01N2333/96405—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general
- G01N2333/96408—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from non-mammals in general with EC number
- G01N2333/96419—Metalloendopeptidases (3.4.24)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Toxicology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261585909P | 2012-01-12 | 2012-01-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2802652T true PT2802652T (pt) | 2019-09-10 |
Family
ID=48782075
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT13736040T PT2802652T (pt) | 2012-01-12 | 2013-01-10 | Enzimas de clostridium histolyticum |
PT191741826T PT3584317T (pt) | 2012-01-12 | 2013-01-10 | Enzima de clostridium histolyticum |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT191741826T PT3584317T (pt) | 2012-01-12 | 2013-01-10 | Enzima de clostridium histolyticum |
Country Status (13)
Country | Link |
---|---|
US (6) | US9757435B2 (pt) |
EP (4) | EP4276180A3 (pt) |
JP (5) | JP6263755B2 (pt) |
AU (6) | AU2013208028B2 (pt) |
BR (1) | BR112014017229B1 (pt) |
CA (2) | CA2861033C (pt) |
DK (2) | DK2802652T3 (pt) |
ES (3) | ES2740499T3 (pt) |
HU (2) | HUE057423T2 (pt) |
MX (1) | MX351448B (pt) |
NZ (5) | NZ750379A (pt) |
PT (2) | PT2802652T (pt) |
WO (1) | WO2013106510A2 (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2859412C (en) * | 2011-12-14 | 2021-05-25 | The Board Of Trustees Of The University Of Arkansas | Delivery of therapeutic agents using bacterial collagen-binding polypeptide segments |
EP4276180A3 (en) * | 2012-01-12 | 2024-01-10 | Endo Global Ventures | Clostridium histolyticum enzyme |
RU2540919C1 (ru) * | 2013-09-27 | 2015-02-10 | Государственное автономное учреждение здравоохранения "Республиканская клиническая больница Министерства здравоохранения Республики Татарстан" | Способ безоперационного лечения контрактуры дюпюитрена iii-iv степени тяжести |
PT107276B (pt) * | 2013-11-07 | 2018-06-07 | Univ Aveiro | Método para produção de colagenase recombinante para digestão de colagénios |
WO2017074257A1 (en) * | 2015-10-26 | 2017-05-04 | Nanyang Technological University | Non-viable derivatives of clostridium sporogenes as anti-cancer therapeutic agents |
EP3551230A1 (en) * | 2016-12-08 | 2019-10-16 | CureVac AG | Rna for treatment or prophylaxis of a liver disease |
US11542490B2 (en) | 2016-12-08 | 2023-01-03 | CureVac SE | RNAs for wound healing |
JP7397440B2 (ja) | 2017-02-10 | 2023-12-13 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー | コラーゲン結合薬剤組成物およびその使用方法 |
AU2018226820B2 (en) | 2017-03-01 | 2022-12-08 | Endo Ventures Limited | Apparatus and method for assessing and treating cellulite |
BR112019020394A2 (pt) | 2017-03-28 | 2020-04-22 | Endo Ventures Ltd | método melhorado de produção de colagenase |
CZ308157B6 (cs) * | 2017-09-13 | 2020-01-29 | MB PHARMA s.r.o. | Kmen bakterie Clostridium histolyticum, kolagenáza připravená s použitím tohoto kmene a její použití |
WO2020021332A2 (en) | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
WO2020021330A2 (en) | 2018-07-12 | 2020-01-30 | Endo Global Aesthetics Limited | Injection techniques for the treatment of cellulite |
CA3112437A1 (en) | 2018-09-18 | 2020-03-26 | Endo Global Aesthetics Limited | Compositions and methods for treating cellulite |
CN109355222B (zh) * | 2018-11-06 | 2020-06-02 | 上海交通大学 | 对水稻白叶枯病菌具有拮抗作用的芽孢杆菌及分离与应用 |
US20220305094A1 (en) | 2019-01-06 | 2022-09-29 | Endo Global Aesthetics Limited | Collagenase formulations and methods of producing the same |
WO2020164721A1 (de) * | 2019-02-14 | 2020-08-20 | Nordmark Arzneimittel Gmbh & Co. Kg | Chromatographische aufreinigung von wenigstens einem enzym, ausgesucht aus der gruppe bestehend aus kollagenase typ i, neutrale protease und clostripain |
CN113025599B (zh) * | 2021-04-02 | 2023-09-12 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌i型胶原酶及其制备方法和应用 |
CN112941058B (zh) * | 2021-04-02 | 2023-12-05 | 重庆科润生物医药研发有限公司 | 一种重组溶组织梭菌ii型胶原酶及其制备方法和应用 |
WO2023112020A1 (en) * | 2021-12-14 | 2023-06-22 | Ramot At Tel Aviv University Ltd. | Modified recombinant collagenase, compositions comprising the same and uses thereof in dental related procedures |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3821364A (en) * | 1966-07-08 | 1974-06-28 | Advance Biofactures Corp | Process of producing collagenase |
JPS5662229A (en) | 1979-10-25 | 1981-05-28 | Asahi Glass Co Ltd | Electro-optical dimming panel |
US4338300A (en) | 1981-02-05 | 1982-07-06 | The Regents Of The University Of California | Use of purified clostridial collangenase in the treatment of Peyronie's disease |
EP0115974B1 (fr) | 1983-01-05 | 1988-09-07 | Institut Pasteur | Préparation à activité collagénolytique ayant une activité élevée et compositions pharmaceutiques la contenant |
US4645668A (en) | 1983-08-04 | 1987-02-24 | Biospecifics, Nv | Method for the prevention and treatment of scars with enzymes |
US4524065A (en) | 1983-08-04 | 1985-06-18 | Bio-Specifics N.V. | Method for the prevention and treatment of scars with enzymes |
US4542065A (en) | 1984-05-21 | 1985-09-17 | Ppg Industries, Inc. | Chemically treated glass fibers and strands and dispersed products thereof |
JPS61289885A (ja) | 1985-06-14 | 1986-12-19 | Nitta Zerachin Kk | コラゲナ−ゼおよびコラゲナ−ゼの製造方法 |
JP2898022B2 (ja) | 1989-09-05 | 1999-05-31 | 株式会社ニッピ | コラーゲン分解酵素の製造方法 |
US5252461A (en) | 1990-05-01 | 1993-10-12 | The Regents Of The Univ. Of California | Mixed immunoglobulins for detection of rheumatoid factors |
CA2047306A1 (en) | 1990-07-23 | 1992-01-24 | Milan Holjevac | Mutant bacterium clostridium histolyticum, a process for the obtaining thereof, and its use in the production of clostripain-free collagenase |
US5393792A (en) | 1991-11-20 | 1995-02-28 | Advance Biofactures Of Curacao, N.V. | High dosage topical forms of collagenase |
US5462739A (en) | 1991-11-21 | 1995-10-31 | Yeda Research And Development Co., Ltd. | Microdelivery device and method for enhanced drug administration to the eye |
US5256140A (en) | 1992-03-27 | 1993-10-26 | Fallien Cosmeceuticals, Ltd. | Composition for levelling skin |
EP0654084A4 (en) * | 1992-06-22 | 1996-07-03 | Trigen Inc | MOLECULAR CLONING OF GENES RESPONSIBLE FOR THE PRODUCTION OF COLLAGENASE FROM -i (CLOSTRIDIUM HISTOLYTICUM). |
WO1994016086A1 (en) | 1992-12-30 | 1994-07-21 | Bioteknologisk Institut | Recombinant lactic acid bacterium containing an inserted promoter and method of constructing same |
JP3186881B2 (ja) | 1993-02-18 | 2001-07-11 | 倉敷紡績株式会社 | 肝細胞の分離方法 |
US5332503A (en) | 1993-04-16 | 1994-07-26 | Baxter International Inc. | Process for purifying collagenase |
US5514340A (en) | 1994-01-24 | 1996-05-07 | Magnetix Biotechnology, Inc. | Device for separating magnetically labelled cells |
JP3028852B2 (ja) | 1994-06-24 | 2000-04-04 | ロシュ ダイアグノスティックス コーポレーション | ヒストリチクス菌から得られるコラゲナーゼおよび2つの他のプロテアーゼの精製混合物 |
US5589171A (en) | 1994-08-22 | 1996-12-31 | Advance Biofactures Of Curacao | Treatment of Dupuytren's disease with collagenase |
CA2158822C (en) | 1994-09-27 | 2008-12-23 | Kusuki Nishioka | Therapeutic agent for rheumatic disease |
US6958150B2 (en) | 1994-12-15 | 2005-10-25 | Advance Biofactures Of Curacao, N.V. | Reduction of adipose tissue |
BR9607143A (pt) | 1995-03-16 | 1997-11-25 | Knoll Ag | Enzima ibtenível de clostridium histolyticum mistura de enzimas uso da mistura uso de enzimas colagenase hp na forma pura colagenase az na forma pura e elastase na forma pura |
US5705170A (en) | 1995-10-24 | 1998-01-06 | Plantech International, Inc. | Herbal cellulite treatments |
US5989888A (en) | 1996-01-24 | 1999-11-23 | Roche Diagnostics Corporation | Purified mixture of collagenase I, collagenase II and two other proteases |
ATE226637T1 (de) | 1996-09-06 | 2002-11-15 | Bioteknologisk Inst | Milchsäurebakterielles regulierbares expressionssystem |
EP0941311B1 (de) * | 1996-11-19 | 2004-07-28 | Boehringer Mannheim Gmbh | Rekombinante collagenase typ i aus clostridium histolyticum und ihre verwendung zur isolierung von zellen und zellverbänden |
US5830741A (en) | 1996-12-06 | 1998-11-03 | Boehringer Mannheim Corporation | Composition for tissue dissociation containing collagenase I and II from clostridium histolyticum and a neutral protease |
US5753785A (en) | 1996-12-16 | 1998-05-19 | Fina Technology, Inc. | Production of E-B copolymers with a single metallocene catalyst and a single monomer |
US6086872A (en) | 1997-03-27 | 2000-07-11 | Advance Biofactures Of Curacao, Nv | Amelioration of dupuytren's disease |
JPH10262658A (ja) | 1997-03-28 | 1998-10-06 | Kikkoman Corp | ザルコシン・オキシダーゼの結晶、その製造方法及び三次元構造 |
TR200001789T2 (tr) | 1997-10-03 | 2000-10-23 | Lavipharm Laboratories, Inc. | Prolamin-bitki kutuplu lipit kompozisyonu, bunun hazırlama ve uygulama metodu |
GB9724802D0 (en) | 1997-11-24 | 1998-01-21 | Unilever Plc | Antiperspirant or deodorant compoistions |
US20020036328A1 (en) | 1998-11-16 | 2002-03-28 | William R. Richards, Jr. | Offset drain fermi-threshold field effect transistors |
FR2788682B1 (fr) | 1999-01-26 | 2001-04-06 | Seb Sa | Dispositif de thermographie |
US6022539A (en) | 1999-06-03 | 2000-02-08 | Advance Biofactures Of Curacao | Amelioration of peyronie's disease |
RU2180002C2 (ru) | 1999-08-16 | 2002-02-27 | Пермское научно-производственное объединение "Биомед" | Способ получения коллагеназы |
JP2003507400A (ja) | 1999-08-20 | 2003-02-25 | ハワード ムラード | セリュライトの出現を軽減する医薬組成物及び方法 |
US6280993B1 (en) * | 1999-08-24 | 2001-08-28 | Ichiro Yamato | Gene encoding class I collagenase |
ITMI991894A1 (it) | 1999-09-09 | 2001-03-09 | Carlo Ghisalberti | Acido linoleico coniugato e trigliceride nuovi metodi di sintesi e d'uso |
PT1923068E (pt) | 1999-09-24 | 2011-07-29 | Proteon Therapeutics Inc | Sistema e métodos para a abertura de condutas biológicas obstruídas |
US7811250B1 (en) | 2000-02-04 | 2010-10-12 | Boston Scientific Scimed, Inc. | Fluid injectable single operator exchange catheters and methods of use |
US20030026844A1 (en) | 2000-04-18 | 2003-02-06 | Hee-Yong Lee | Injectable sustained release pharmaceutical composition and processes for preparing the same |
JP4399158B2 (ja) | 2000-10-20 | 2010-01-13 | バイオニアー エイ/エス | 乳酸菌における異種遺伝子産物の製造のための改良発酵法 |
AU3104102A (en) | 2000-12-18 | 2002-07-01 | Univ Texas | Local regional chemotherapy and radiotherapy using in situ hydrogel |
AU2002251831A1 (en) | 2001-01-30 | 2002-08-12 | The Regents Of The University Of Michigan | Methods for sustained release local delivery of drugs for ablation of unwanted tissue |
WO2003004628A2 (de) | 2001-07-02 | 2003-01-16 | Nordmark Arzneinmittel Gmbh & Co. Kg | Verfahren zur aufreinigung eines enzyms und hiernach hergestelltes, aufgereinigtes enzym sowie verwendung des enzyms |
GB0124124D0 (en) | 2001-10-08 | 2001-11-28 | Medical Res Council | Methods of treatment |
JP2003284553A (ja) | 2002-03-28 | 2003-10-07 | Seikagaku Kogyo Co Ltd | 生理活性タンパク質 |
CA2490725A1 (en) | 2002-06-25 | 2003-12-31 | Ultrashape Inc. | Devices and methodologies useful in body aesthetics |
EP1433845A1 (en) * | 2002-12-23 | 2004-06-30 | Georg-August-Universität | Clostridium tetani collagenase and uses thereof |
EP1462519A1 (en) | 2003-03-24 | 2004-09-29 | Boehringer Ingelheim Austria GmbH | Method and devices for producing biomolecules |
JP4205496B2 (ja) | 2003-06-19 | 2009-01-07 | 三菱化学株式会社 | 新規カルボニル還元酵素及びこれをコードするdna、ならびにこれらを利用した光学活性アルコールの製造方法 |
EP1709194A4 (en) | 2003-12-17 | 2007-07-25 | Univ Columbia | ADMINISTRATION OF DNA OR RNA THROUGH LACUNAR JUNCTION OF HOST CELLS TO TARGET CELLS AND CELL-BASED DELIVERY SYSTEM FOR ANTISENSE OR ARNS |
EP2532742B1 (en) | 2004-01-30 | 2018-08-08 | Shire Pharmaceuticals Ireland Limited | Recombinant arylsulfatase A for reducing galatosyl sulphatide levels in a subject |
CA2562024C (en) | 2004-04-07 | 2014-05-27 | Rinat Neuroscience Corp. | Methods for treating bone cancer pain by administering a nerve growth factor antagonist |
US7754230B2 (en) | 2004-05-19 | 2010-07-13 | The Regents Of The University Of California | Methods and related compositions for reduction of fat |
TR201802446T4 (tr) | 2004-05-19 | 2018-03-21 | Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct | Sodyum deoksikolat içeren enjeksiyonluk bileşim. |
US7355027B2 (en) | 2004-06-16 | 2008-04-08 | Dynport Vaccine Company Llc | Bacillus anthracis protective antigen |
PT1781697E (pt) | 2004-07-07 | 2009-06-25 | Lundbeck & Co As H | Nova epo carbamilada e método para a sua produção |
CA2572765C (en) | 2004-07-08 | 2013-05-21 | Amgen Inc. | Compound having improved bioefficiency when administered in a multidose regimen |
US20060020448A1 (en) | 2004-07-21 | 2006-01-26 | Microsoft Corporation | Method and apparatus for capitalizing text using maximum entropy |
JP4923131B2 (ja) | 2004-08-30 | 2012-04-25 | 株式会社リコー | ログ収集システム、ログ収集装置およびログ収集プログラム |
JP4976131B2 (ja) | 2004-08-30 | 2012-07-18 | 株式会社ダイセル | ポリグリセリンモノエーテル及びその製造方法 |
US20150025420A1 (en) | 2004-10-06 | 2015-01-22 | Guided Therapy Systems, Llc | Ultrasound treatment device and methods of use |
DE102004060075A1 (de) | 2004-12-14 | 2006-07-06 | Merck Patent Gmbh | Verfahren zur Herstellung von Onium-Salzen mit Dialkylphosphat-, Dialkylphosphinat oder (O-Alkyl)-alkyl- oder Alkyl-phosphonat-Anionen mit geringem Halogenid-Gehalt |
US20070224184A1 (en) | 2006-02-22 | 2007-09-27 | The Research Foundation Of The State University Of New York | Method for treating cellulite |
PT1846022E (pt) | 2005-01-21 | 2015-09-03 | Univ New York State Res Found | Métodos para o tratamento de capsulite adesiva |
US7854929B2 (en) | 2005-01-21 | 2010-12-21 | The Research Foundation Of State University Of New York | Method for treating lateral epicondylitis using collagenase |
JP2006254876A (ja) | 2005-03-18 | 2006-09-28 | Hokkaido Univ | L−トリプトファン製造法 |
US20060241673A1 (en) | 2005-04-21 | 2006-10-26 | Zadini Filiberto P | Subcision device |
US20060251581A1 (en) | 2005-05-09 | 2006-11-09 | Mcintyre Jon T | Method for treatment of uterine fibroid tumors |
US20070003541A1 (en) | 2005-07-01 | 2007-01-04 | Rodolfo Faudoa | Methods and compositions for therapeutics |
ITPD20050207A1 (it) | 2005-07-07 | 2007-01-08 | Fidia Farmaceutici | Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere |
US20070031482A1 (en) | 2005-08-02 | 2007-02-08 | Ceramoptec Industries, Ind. | PDT treatment method for cellulites and cosmetic use |
US7811560B2 (en) | 2006-01-30 | 2010-10-12 | Auxilium Us Holdings, Llc | Compositions and methods for treating collagen-mediated diseases |
WO2007100590A2 (en) | 2006-02-22 | 2007-09-07 | Auxilium Pharmaceuticals, Inc. | Methods for treating cellulite |
EP2001561A2 (en) | 2006-03-31 | 2008-12-17 | DSMIP Assets B.V. | Novel use of compounds and combinations of compunds for improving the physical appearance |
WO2008100833A2 (en) | 2007-02-13 | 2008-08-21 | Auxilium International Holdings, Inc. | Production of recombinant collagenases colg and colh in escherichia coli |
US8617543B2 (en) | 2007-02-14 | 2013-12-31 | Yolare Pharmaceuticals, LLC | Modified mutant collagenase and its use in fat melting and in scar reduction |
CN101677912B (zh) | 2007-05-11 | 2013-06-12 | 希格马托制药工业公司 | 可用于递送化妆品活性成分的凝胶 |
US9987221B2 (en) | 2007-08-23 | 2018-06-05 | Boston Scientific Scimed, Inc. | Injectable hydrogel compositions |
KR101633612B1 (ko) | 2007-10-26 | 2016-06-27 | 코닌클리케 필립스 엔.브이. | 광각 선택 광 검출기 장치 |
WO2009059379A1 (en) | 2007-11-07 | 2009-05-14 | Dynamic Microbials Limited | Antimicrobial compositions, formulations and uses thereof |
US20100159564A1 (en) * | 2007-11-30 | 2010-06-24 | Dwulet Francis E | Protease resistant recombinant bacterial collagenases |
ES2388219T3 (es) | 2008-06-02 | 2012-10-10 | F. Hoffmann-La Roche Ag | Purificación mejorada de colagenasas a partir de un cultivo líquido de Clostridium histolyticum |
US8236356B2 (en) | 2008-06-11 | 2012-08-07 | Roche Diagnostics Operations, Inc. | Growth medium for Clostridium histolyticum |
CN102105133B (zh) | 2008-07-21 | 2015-06-17 | 奥德纳米有限公司 | 控制释放型耳结构调节和先天性免疫系统调节组合物以及治疗耳部病症的方法 |
US8380531B2 (en) | 2008-07-25 | 2013-02-19 | Invivodata, Inc. | Clinical trial endpoint development process |
US20110160617A9 (en) | 2008-10-22 | 2011-06-30 | Allergan, Inc. | Clinical assessment scales and methods |
BRPI0921679A2 (pt) | 2008-11-11 | 2016-02-16 | Sigma Tau Ind Farmaceuti | composto útil para tratar celulite |
DK2363461T3 (en) * | 2008-11-19 | 2015-03-02 | Meiji Seika Pharma Co Ltd | Fusion collagenase associated with affinity tags, and process for its preparation |
IT1397646B1 (it) * | 2009-12-15 | 2013-01-18 | Seidita | Collagenasi ricombinanti di c. histolyticum e metodo per la loro produzione. |
US9132199B2 (en) | 2010-03-05 | 2015-09-15 | University of Pittsburgh—of the Commonwealth System of Higher Education | Reverse thermal gels and uses therefor |
US20130195828A1 (en) | 2010-04-14 | 2013-08-01 | Northwestern University | Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques |
US20130217789A1 (en) | 2010-09-03 | 2013-08-22 | North Carolina Central University | Biodegradable liquogel and ph sensitive nanocarriers |
ES2385239B1 (es) * | 2010-09-30 | 2013-06-19 | Proteos Biotech S.L.U. | Uso de colagenasa g recombinante, colagenasa h recombinante y pz-peptidasa recombinante para el tratamiento de enfermedades que cursan con alteraciones del colágeno. |
WO2012112940A1 (en) | 2011-02-18 | 2012-08-23 | Kythera Biopharmaceuticals, Inc. | Treatment of submental fat |
US10119131B2 (en) | 2011-03-16 | 2018-11-06 | Biospecifics Technologies Corp. | Compositions and methods for producing clostridial collagenases |
TWI461214B (zh) | 2011-06-13 | 2014-11-21 | Univ Chang Gung | Biodegradable water-sensitive glue, a drug delivery system as a carrier thereof, and a pharmaceutical composition for the treatment and / or prevention of eye diseases |
WO2013059263A1 (en) | 2011-10-17 | 2013-04-25 | Sound Surgical Technologies, Llc | Ultrasonic probe for treating cellulite |
BR112014009785B1 (pt) | 2011-10-21 | 2020-06-30 | Auxilium International Holdings, Inc. | método cosmético para tratar ou reduzir panniculopatia fibrosclerótica edematória (pef) |
EP4276180A3 (en) | 2012-01-12 | 2024-01-10 | Endo Global Ventures | Clostridium histolyticum enzyme |
CN104603616B (zh) | 2012-09-07 | 2017-03-08 | 株式会社资生堂 | 使用纤蛋白‑3和/或肌聚糖γ作为指标评价脂肪团的方法和评价脂肪团有效药物的方法 |
CA2905756C (en) | 2013-03-15 | 2016-11-29 | Mary Kay Inc. | Cosmetic compositions for reducing the appearance of cellulite or improving skin texture |
DK2968484T3 (da) | 2013-03-15 | 2021-02-22 | Biospecifics Tech Corporation | Behandlingsfremgangsmåde og produkt til uterus fibromer, som anvender oprenset kollagenase |
US20160000890A1 (en) | 2013-03-15 | 2016-01-07 | Biospecifics Technologies Corp. | Thermosensitive hydrogel collagenase formulations |
CN103751102A (zh) | 2014-01-15 | 2014-04-30 | 上海交通大学 | 一种胶原酶温敏水凝胶及其制备方法和应用 |
KR101896087B1 (ko) | 2014-06-27 | 2018-09-06 | 주식회사 메디톡스 | 지방 감소를 위한 담즙산 및 염의 방법 및 조성물 |
CA3013776A1 (en) | 2016-02-08 | 2017-08-17 | OutcomeMD, Inc. | Determining a wellness, improvement, or effectiveness score |
WO2018077825A1 (en) | 2016-10-28 | 2018-05-03 | Merz Pharma Gmbh & Co. Kgaa | Treatment of gynoid lipodystrophy |
AU2018226820B2 (en) | 2017-03-01 | 2022-12-08 | Endo Ventures Limited | Apparatus and method for assessing and treating cellulite |
BR112019020394A2 (pt) | 2017-03-28 | 2020-04-22 | Endo Ventures Ltd | método melhorado de produção de colagenase |
-
2013
- 2013-01-10 EP EP23185957.0A patent/EP4276180A3/en active Pending
- 2013-01-10 ES ES13736040T patent/ES2740499T3/es active Active
- 2013-01-10 NZ NZ750379A patent/NZ750379A/en unknown
- 2013-01-10 CA CA2861033A patent/CA2861033C/en active Active
- 2013-01-10 WO PCT/US2013/020940 patent/WO2013106510A2/en active Application Filing
- 2013-01-10 PT PT13736040T patent/PT2802652T/pt unknown
- 2013-01-10 ES ES21208743T patent/ES2968836T3/es active Active
- 2013-01-10 NZ NZ627372A patent/NZ627372A/en unknown
- 2013-01-10 CA CA2970639A patent/CA2970639C/en active Active
- 2013-01-10 BR BR112014017229-3A patent/BR112014017229B1/pt active IP Right Grant
- 2013-01-10 JP JP2014552282A patent/JP6263755B2/ja active Active
- 2013-01-10 HU HUE19174182A patent/HUE057423T2/hu unknown
- 2013-01-10 NZ NZ766918A patent/NZ766918A/en unknown
- 2013-01-10 DK DK13736040.0T patent/DK2802652T3/da active
- 2013-01-10 HU HUE13736040A patent/HUE046160T2/hu unknown
- 2013-01-10 NZ NZ733709A patent/NZ733709A/en unknown
- 2013-01-10 NZ NZ718173A patent/NZ718173A/en unknown
- 2013-01-10 ES ES19174182T patent/ES2904884T3/es active Active
- 2013-01-10 DK DK19174182.6T patent/DK3584317T5/da active
- 2013-01-10 EP EP13736040.0A patent/EP2802652B1/en active Active
- 2013-01-10 EP EP19174182.6A patent/EP3584317B1/en active Active
- 2013-01-10 EP EP21208743.1A patent/EP4015627B1/en active Active
- 2013-01-10 PT PT191741826T patent/PT3584317T/pt unknown
- 2013-01-10 MX MX2014008441A patent/MX351448B/es active IP Right Grant
- 2013-01-10 AU AU2013208028A patent/AU2013208028B2/en active Active
-
2014
- 2014-07-11 US US14/328,772 patent/US9757435B2/en active Active
-
2016
- 2016-07-28 AU AU2016208384A patent/AU2016208384C1/en active Active
- 2016-07-28 AU AU2016208378A patent/AU2016208378B2/en active Active
-
2017
- 2017-08-04 US US15/669,286 patent/US10603365B2/en active Active
- 2017-11-22 JP JP2017224394A patent/JP6496386B2/ja active Active
-
2019
- 2019-01-11 AU AU2019200192A patent/AU2019200192B2/en active Active
- 2019-02-06 JP JP2019019694A patent/JP6752309B2/ja active Active
-
2020
- 2020-03-11 US US16/816,097 patent/US11975054B2/en active Active
- 2020-08-18 JP JP2020138009A patent/JP6947888B2/ja active Active
-
2021
- 2021-08-25 AU AU2021221653A patent/AU2021221653B2/en active Active
- 2021-09-16 JP JP2021150945A patent/JP7354197B2/ja active Active
-
2023
- 2023-06-28 US US18/342,874 patent/US11879141B2/en active Active
- 2023-06-28 US US18/329,308 patent/US20240252602A1/en active Pending
- 2023-09-12 AU AU2023229488A patent/AU2023229488A1/en active Pending
-
2024
- 2024-03-25 US US18/615,520 patent/US20240269245A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PT2802652T (pt) | Enzimas de clostridium histolyticum | |
ZA201600633B (en) | Variant enzymes | |
HK1207880A1 (en) | Improved enzyme variants | |
EP2866024A4 (en) | ENZYMATIC ELECTRODE | |
EP2751265A4 (en) | NEW CELLOBIOHYDROLASES | |
ZA201500911B (en) | Enzymes | |
EP2880050A4 (en) | NOVEL ENZYMES, ENZYME COMPONENTS AND USES THEREOF | |
EP2866025A4 (en) | ENZYMATIC ELECTRODE | |
HK1198445A1 (en) | On-column enzymatic cleavage | |
HK1216999A1 (zh) | 針對艱難梭菌的抗體 | |
GB201214938D0 (en) | Alternative oxidase | |
IL237172A0 (en) | פוליפפטידים של clostridium difficile כתרכיבים | |
GB201207018D0 (en) | Enzymes | |
EP2995681A4 (en) | NOVEL DNA COLUMN ENZYME | |
ZA201400850B (en) | Enzyme system | |
HK1211323A1 (en) | Dual enzymatic amplification | |
GB201209420D0 (en) | Prognostic gene | |
GB201211978D0 (en) | Enzyme | |
EP2818559A4 (en) | ENZYME TEST PROCEDURE | |
GB201223308D0 (en) | Enzyme inhibitors | |
EP2970932A4 (en) | ENZYMES WITH PULLULANASE ACTIVITY | |
GB201207952D0 (en) | Restriction enzymes | |
GB201215883D0 (en) | Enzyme inhibition | |
GB201215856D0 (en) | Enzyme inhibition | |
GB201318464D0 (en) | Modified enzymes |